The difference between pralsetinib and pravatinib

Pralsetinib (Pralsetinib) and pravatinib are both effective drugs for the treatment of thyroid cancer, but they differ in indications, targeting effects, tolerance and dosage. Platinib is mainly used to treat advanced or metastatic non-small cell lung cancer and thyroid cancer with RET gene mutations. Pravatinib can be used to treat thyroid cancer with RET mutations and is also suitable for multiple endocrine neoplasia syndrome type 2B (MEN2B).

Platinib and pravatinib are both inhibitors targeting RET protein kinase, but their inhibitory effects on other kinases are slightly different. Platinib is more selective for RET kinase and interferes less with other related kinases. It has shown good tolerance in clinical trials and has relatively few side effects. The recommended dose is 400 mg orally once a day. Pravatinib can cause a range of side effects, including heart problems, skin reactions and gastrointestinal discomfort. Its dosage is based on the patient's weight and kidney function, usually 300 mg orally once a day.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.